How does Roivant Sciences Ltd. (ROIV) change from a tortoise to a hare?

Roivant Sciences Ltd. (NASDAQ: ROIV) stock jumped 0.34% on Friday to $8.78 against a previous-day closing price of $8.75. With 2.23 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.89 whereas the lowest price it dropped to was $8.65. The 52-week range on ROIV shows that it touched its highest point at $10.00 and its lowest point at $2.52 during that stretch. It currently has a 1-year price target of $13.57.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ROIV was down-trending over the past week, with a drop of -12.02%, but this was up by 33.23% over a month. Three-month performance surged to 105.62% while six-month performance rose 94.25%. The stock gained 26.88% in the past year, while it has gained 9.89% so far this year. A look at the trailing 12-month EPS for ROIV yields -1.70 with Next year EPS estimates of -1.32. For the next quarter, that number is -0.35. This implies an EPS growth rate of -6.80% for this year and 7.70% for next year.


Float and Shares Shorts:

At present, 699.89 million ROIV shares are outstanding with a float of 440.82 million shares on hand for trading. On Oct 13, 2022, short shares totaled 11.68 million, which was 1.66% higher than short shares on Sep 14, 2022. In addition to Mr. Vivek Ramaswamy as the firm’s Founder & Chairman, Mr. Matthew Gline serves as its CEO & Director.

Institutional Ownership:

Through their ownership of 51.34% of ROIV’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 4.33% of ROIV, in contrast to 31.28% held by mutual funds. Shares owned by individuals account for 30.03%. As the largest shareholder in ROIV with 16.11% of the stake, QVT Financial LP holds 116,885,455 shares worth 116,885,455. A second-largest stockholder of ROIV, Viking Global Investors LP, holds 88,238,700 shares, controlling over 12.16% of the firm’s shares. Two Seas Capital LP is the third largest shareholder in ROIV, holding 5,869,690 shares or 0.81% stake.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ROIV since 9 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ROIV analysts setting a high price target of $19.00 and a low target of $10.00, the average target price over the next 12 months is $13.13. Based on these targets, ROIV could surge 116.4% to reach the target high and rise by 13.9% to reach the target low. Reaching the average price target will result in a growth of 49.54% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ROIV will report FY 2023 earnings on 06/27/2023. Analysts have provided yearly estimates in a range of -$1.21 being high and -$1.70 being low. For ROIV, this leads to a yearly average estimate of -$1.49. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Roivant Sciences Ltd. surprised analysts by $0.09 when it reported -$0.29 EPS against a consensus estimate of -$0.38. The surprise factor in the prior quarter was -$0.16. Based on analyst estimates, the high estimate for the next quarter is -$0.32 and the low estimate is -$0.39. The average estimate for the next quarter is thus -$0.35.

Leave a Comment

Your email address will not be published. Required fields are marked *